



## Alliance *for* Lupus Research

PREVENT. TREAT. CURE.

Since its founding, the *Alliance for Lupus Research* (ALR) has given more money to lupus research than any non-governmental agency in the world. To date, the ALR has committed over \$72 million to lupus research.

### **OUR RESEARCH FUNDING MECHANISMS:**

<b>Target Identification in Lupus Grant (TIL) Program</b>	<b>Functional Genomics and Molecular Pathways (FGMP) in SLE Grant Program</b>	<b>International SLE Genetics Initiative (SLEGEN)</b>
<p>Under our TIL grant program, investigators leverage a two-year, up-to-\$400,000 award to remove the barriers to new treatments and a possible cure. A third year of funding for up-to-\$200,000 may be granted following the submission of a non-competitive progress report. All lupus research funded under the TIL program is based on realizable goals for translation into therapeutic discovery programs – that is, research that can move quickly from the laboratory to the patient’s bedside.</p>	<p>Under our FGMP grant program, investigators receive Research grants of up to \$350,000 for two years or Pilot Grants of up to \$75,000 for one year. Grantees will focus on determining how the genes identified as a result of the SLEGEN Initiative may have a role in lupus, and provide further information about the molecular pathways modulated by these genes.</p>	<p>Launched in 2005, this special initiative is designed to accelerate the search for genes that put people at risk for developing systemic lupus erythematosus (SLE or lupus). The SLEGEN Initiative facilitates this by pooling patient samples collected from the International SLE Genetics Consortium, which includes many scientists working on the genetics of lupus.</p> <p>In 2011, the ALR funded a study that helped the SLEGEN Consortium to utilize the most advanced technology available, called the ImmunoChip, to more closely examine the genes that were identified by SLEGEN in the past.</p>

If you have any questions about any of the above, please contact Diomaris Gonzalez, Assistant Director of Research Administration at [dgonzalez@lupusresearch.org](mailto:dgonzalez@lupusresearch.org) or 212-218-2840.

		<i>Investigator</i>	<i>Institution</i>	<i>State</i>	<i>Project Title</i>
Target Identification in Lupus Grants	2012	Dai, Rujuan, PhD	Virginia Polytechnic Institute and State University	VA	Targeting the miR-182-96-183 cluster to ameliorate lupus
		Kelley, Vicki, PhD	Brigham and Women's Hospital	MA	Distinguishing CSF-1 and IL-34 As Therapeutic Targets for Lupus Nephritis
		Laufer, Terri, MD	University of Pennsylvania	PA	Follicular helper T cells: altered differentiation in Lupus
		Mayadas, Tanya, PhD	Brigham and Women's Hospital	MA	Analysis and treatment of organ damage in a humanized mouse model of Lupus
		Pernis, Alessandra, MD	The Hospital for Special Surgery	NY	Effector Tregs in lupus
		Ueno, Hideki, MD, PhD	Baylor Research Institute	TX	Altered T follicular helper cell subsets in active pediatric lupus
		Utz, Paul, MD	Stanford University	CA	SLE Target Identification Using CyTOF and Multiplexed Assays
		Wither, Joan, MD, PhD	University Health Network (Toronto, Canada)	--	Identification of Biomarkers for Patient Stratification in Lupus Nephritis
		Yan, Nan, PhD	UT Southwestern Medical Center	TX	Identification of endogenous nucleic acids as targets in lupus
	2011	Barnes, Betsy, PhD	UMDNJ - New Jersey Medical School	NJ	Targeting IRF5 activation for the treatment of lupus
		Craft, Joseph, MD	Yale University	NJ	Follicular Helper T Cells in SLE: Characterization and Therapeutic Targets
		Datta, Syamal, MBBS	Northwestern University - Chicago Campus	IL	Peptide Vaccine Suppressing Autoantigen-Specific Response in Human Lupus
		Denny, Michael, PhD	Temple University	PA	Abnormal Neutrophil Development in SLE
		Diamond, Betty, MD	The Feinstein Institute for Medical Research	NY	Dendritic cell dysfunction as a path to SLE
		Fu, Shu Man, MD, PhD	University of Virginia	VA	Progressions and Biomarkers of Proliferative Lupus Nephritis
		Jefferies, Caroline, PhD	Royal College of Surgeons in Ireland (Dublin, Ireland)	--	Ro52 and Siglec-E as therapeutic targets in SLE
		Kaplan, Mariana, MD	University of Michigan	MI	Lupus and the inflammasome
		Pillai, Shiv, PhD, MBBS	Massachusetts General Hospital	MA	Targeting the SIAE pathway in lupus
		Pisetsky, David, MD, PhD	Duke University Medical Center	NC	Nucleic Acid Binding Polymers in the Treatment for SLE
Functional Genomics and Molecular Pathways in SLE Grants	2012	Sharma, Shruti, PhD	University of Massachusetts Medical School	MA	Innate sensing of AT-rich DNA during autoimmunity
		Bucala, Richard, MD, PhD	Yale University	CT	Function of the Polymorphic MIF Locus in SLE
		Buckner, Jane, MD	Benaroya Research Institute at Virginia Mason	WA	The Impact of Genetic Variants on B cell Development and Function in SLE
		Crispin, Jose, MD	Beth Israel Deaconess Medical Center	MA	Mechanisms through which protein phosphatase 2A (PP2A) promotes SLE
		Deng, Yun, MD	University of California, Los Angeles	CA	Dose differential miRNA binding explain allelic risk of TLR7 for SLE
		Feng, Di, PhD	UMDNJ-New Jersey Medical School	NJ	Identifying IRF5-mediated pathways in normal and SLE B cells
		Gregersen, Peter, MD	The Feinstein Institute for Medical Research	NY	Functional Analysis of Csk: A Newly Defined Risk Gene for Lupus
		Means, Terry, PhD	Massachusetts General Hospital	MA	In vivo validation and characterization of allelic variants in lupus
		Tansey, William, PhD	Vanderbilt University Medical Center	TN	Characterization of PHRF1; a ubiquitin ligase implicated in SLE
	Tsao, Betty, PhD	University of California, Los Angeles	CA	Functional Genomics of SLE-associated SMG7/NMNAT2 Locus	
	2011	Atkinson, John, MD	Washington University School of Medicine	MO	Complement Mutations in End Stage Renal Disease Lupus Patients
		Criswell, Lindsey Ann, MD, PhD	University of California - San Francisco	CA	Functional Genomics and Pathway Analysis of the MCH Region in SLE
		Crow, Yanick, PhD	University of Manchester (Manchester, UK)	--	Pathways Linking Tartrate Resistant Acid Phosphatase, Interferon, and Lupus
		Roopenian, Derry, PhD	The Jackson Laboratory	ME	Novel Approach to Modeling the Functional Genomics of Human SLE in Mice
		Satterthwaite, Anne, PhD	University of Texas Southwestern Medical Center	TX	Functional Relationships Between the Lupus Susceptibility Loci Lyn and Ets1
		Siminovitch, Katherine, MD	University Health Network (Toronto, Canada)	--	Defining Functional Implications of a Human SLE Risk Allele in Mice
	SLEGEN 2011	ImmunoChip	University of Alabama at Birmingham	AL	SLE Genetics Consortium